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Early stage oral cavity squamous cell carcinoma (OCSCC) has a significant risk of 
subclinical nodal metastases, which is the strongest independent prognostic factor 
for regional recurrence and survival. However current preoperative imaging modali-
ties are unable to identify patients with micrometastases, and an observation strategy 
has been associated with inferior outcomes when compared to an elective neck dis-
section. Sentinel lymph node biopsy provides a safe and accurate staging procedure 
to select the patients who benefit from an elective neck dissection, while avoiding 
unnecessary surgery in the patients who are node negative. There is recent Level 
II evidence demonstrating equivalent oncological outcomes when compared with 
elective neck dissection. However, a multidisciplinary approach is required including 
reliable mapping of the sentinel lymph node, precise surgical technique and compre-
hensive histopathological analysis to ensure accurate results are obtained.
Keywords: Oral squamous cell carcinoma, oral cancer, head and neck cancer,  
sentinel lymph node, elective neck dissection, nodal metastases, lymphoscintigraphy
1. Introduction
Early stage oral cavity squamous cell carcinoma (T1N0 or T2N0) has a significant 
risk of between 20 and 44% [1–3] of harbouring subclinical nodal metastases. The 
presence of nodal metastases has been shown to be the strongest independent prognos-
tic factor for predicting a poor outcome [4–6]. Current imaging techniques including 
computed tomography (CT), magnetic resonance imaging (MRI), positron emission 
tomography (PET) and ultrasound (US) cannot accurately identify micrometastases 
preoperatively [7, 8]. Traditionally the only way to identify this was to perform an elec-
tive neck dissection (END), however this is unnecessary in the majority (60–80%) of 
patients who do not harbour occult nodal metastases, and has an associated morbidity 
[1]. This chapter will present the histopathological factors that have been used to risk 
stratify patients for an END, as well as the multifaceted technique and role of sentinel 
lymph node biopsy (SLNB) as a staging procedure for patients with OCSCC.
2. Histopathological factors
Various parameters have been investigated to further stratify the risk of sub-
clinical nodal metastases, including tumour thickness and depth of invasion (DOI). 
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Tumour thickness measures the thickness of the tumour from the deepest point of 
invasion to the top of the granular cell layer, or if ulcerated, the ulcer base serves 
as the reference point. DOI is measured from the level of the basement membrane 
to the deepest point of invasion, and in the case of an ulcerated OCSCC, this level 
is estimated by creating an imaginary line from the adjacent basement membrane 
[1]. This avoids under-representing an ulcerated tumour or over-representing 
an exophytic tumour, and has been included in staging for OCSCC in the current 
8th edition American Joint Committee on Cancer (AJCC) staging manual [9]. An 
increased risk of subclinical nodal metastases has been associated with varying 
tumour thicknesses, between 2 mm to 5 mm, with thicker tumours having a risk 
of nodal metastases between 44 and 50% [1, 8, 10]. The anatomical sub-site of the 
OCSCC may also play a role with a lesion thickness > 1.5 mm on the floor of mouth 
being associated with a risk of nodal metastases of 35% [11]; however, this has not 
been a consistent finding, with another study demonstrating a 4 mm cut-off associ-
ated with an increased risk of nodal metastases regardless of sub-site [5]. This study 
documented rates of local control, nodal disease, and survival rates of 91%, 8%, 
and 100%, respectively, for lesions <4 mm thick compared with 84%, 48%, and 
74% for those ≥4 mm thick (p < .01). Despite this there are limitations with basing 
management decisions on the tumour thickness or DOI, as often this may not be 
assessable on a biopsy alone due to the sparse amount of biopsy material, and if 
assessable the biopsy may not be representative of the entire tumour [12], resulting 
in subsequent management decisions based more on clinical assessment.
Histopathological factors predicting for sub-clinical nodal metastases in the 
setting of sentinel lymph node biopsy (SLNB) have also been investigated with 
three variables identified including grade (G1 vs G2/G3), presence of lymphatic 
invasion and mode of invasion (cohesive vs dissolute) [13]. Interestingly, in this 
study DOI and tumour thickness were not reliable predictors of nodal metastasis 
demonstrating the inconsistency and uncertainty in basing management decisions 
on histopathological factors alone.
3. Benefit of elective neck dissection
Superior outcomes have been published in a prospective randomised controlled 
trial (RCT) involving patients with early OCSCC (T1/T2 tumours) without clinical 
evidence of nodal metastases, when they underwent an END compared to observa-
tion followed by neck dissection in the setting of nodal relapse [14]. In this study 
3 year overall survival was 80% for patients undergoing END compared to 67.5% 
for patients undergoing delayed therapeutic dissection following relapse (p = 0.01). 
Subclinical nodal positivity in the END group was 29%, while nodal relapse rates in 
the observation group was 45% [14].
Of note in the ‘true’ node negative patients in this study, which included 
pathological node negative patients in the END group and those who did not 
relapse in the observation group, survival was equivalent. This demonstrates that 
while patients with subclinical nodal metastases benefit from a neck dissection, 
the remaining 60–80% of patients without nodal metastases do not experience a 
survival benefit by undergoing a neck dissection (see Figure 1). It is also important 
to consider that even patients with a pathologically negative neck following END 
have a rate of regional failure up to 5–10% [3, 15].
This benefit of END has been reported in a previous observational study where 
patients with early (T1/T2) OCSCC had significantly improved outcomes undergo-
ing END (median survival 12 years) compared to observation (median survival 
4.1 years), with the majority (11/12) of recurrences in the observation group 
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occurring as regional failures [2]. This benefit is selectively achieved in patients 
undergoing SLNB, as patients with a positive sentinel lymph node (SLN) undergo 
a completion neck dissection while the morbidity of the neck dissection is avoided 
when the SLNB is negative.
4. Technique of sentinel lymph node biopsy
There is marked heterogeneity in the published data assessing the role of SLNB 
in OCSCC including preoperative investigations, technique of identifying the SLN 
and the pathological assessment of the specimens [16]. The GETTEC (Groupe 
d’Etude des Tumeurs de la Tête et du Cou) guidelines [17] have attempted to 
standardise the technique in performing SLNB with recommendations for lympho-
scintigraphy, surgery and pathological analysis. Of note, they recommend a median 
of three SLNs to be sampled, with a single SLN node considered insufficient to 
accurately determine the nodal pathological status.
SLNB for OCSCC presents unique challenges in relation to both the complex 
anatomy of the head and neck, in addition to the short distance between the 
primary lesion and the draining nodal basin, particularly for lesions located in the 
floor of mouth. This is due to the high activity at the adjacent injection site, which 
can be easily overlooked by planar lymphoscintigraphy and intraoperative gamma 
probes [18]. Intraoperatively, the close relationship between the primary lesion 
and the draining lymph nodes can result in so called ‘shine through’ of the radioac-
tive tracer from the primary site with difficulties in identifying the SLN if it is in 
an adjacent nodal basin, particularly the submental (IA) and submandibular (IB) 
basins. Composite single photon emission computed tomography (SPECT) with 
concurrent CT combines functional and anatomical imaging to enhance topo-
graphic orientation and diagnostic sensitivity, with more SLNs being detectable 
than by planar lymphoscintigraphy alone, as well as providing more detailed ana-
tomical information to assist with intraoperative localisation [19]. Figures 2 and 3 
demonstrates the lymphoscintigraphy result and composite SPECT/CT for patients 
with unilateral and bilateral lymphatic drainage respectively. The SPECT/CT 
provides detailed anatomical information to assist with identification of the SLN.
Another consideration that may impact on the accuracy of lymphoscintigra-
phy is the choice of radiotracer. These have different molecular characteristics as 
Figure 1. 
Overall survival in ‘true node negative’ and ‘true node positive’ patients [14].
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summarised in Table 1, which impacts the drainage characteristics, and this may be 
utilised to counteract the ‘shine through’ effect. The potential of [99mTc]Tilmanocept 
is of particular interest as it has a small molecular size of 7 nm facilitating rapid 
injection site clearance, and targets the CD206 receptor found on the reticuloendo-
thelial cells in lymph nodes to promote accumulation within the SLN while reducing 
drainage to second tier nodes [21, 22]. A study assessing [99mTc]Tilmanocept in 
the setting of both OSCC and head and neck cutaneous SCC demonstrated a SLN 
detection rate of 97.6%, with a false negative rate of 2.56% [22]. This study included 
Figure 3. 
Lymphoscintigraphy and SPECT/CT demonstrating bilateral drainage from a lateralised tumour.









99mTC labelled radiotracers [20].
Figure 2. 
Lymphoscintigraphy and SPECT/CT demonstrating ipsilateral level 2 sentinel lymph node.
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20 patients with floor of mouth OSCCs, where [99mTc]Tilmanocept may be of 
particular use, and a SLN was successfully identified in all cases without any false 
negatives [22]. A recent comparison study between [99mTc]Tilmanocept and [99mTc]
Nanocolloid found that [99mTc]Tilmanocept had higher rates of clearance from the 
primary injection site but also had reduced accumulation within the SLN, with a 
similar SLN to injection site ratio of radioactivity between the two radiotracers [23]. 
Figure 4. 
Focused field of view with use of collimator. (This image is © 2021 Devicor Medical Products, Inc.; used with 
permission).
Figure 5. 
Sentinel lymph node with blue dye on one surface facilitating visual identification.
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Figure 6. 
Serial sectioning a lymph node.
This study demonstrated a high degree of agreement in the identification of SLNs 
between each radiotracer, however it is difficult to draw definitive conclusions with 
a small sample size, and further studies are required.
Specific surgical techniques can be employed to counteract the ‘shine through’ 
effect, including mobilisation of the fat pad between the submandibular gland and 
anterior belly of digastric to reflect the tissue, allowing for careful analysis with 
the handheld gamma probe while avoiding radiation from the primary tumour 
injection site [24]. A probe with an angled head (Neoprobe, Devicor Medical 
Products) with collimator attached is indispensable in such narrow spaces as in 
the neck to reliably locate the node. The collimator serves to decrease the field of 
view from 120 to 50 degrees while simultaneously increasing the spatial resolution 
of the probe (see Figure 4). Selective use of patent blue dye (Aspen Pharmacare) 
when the draining lymph nodes are in the submental and submandibular basins 
provides additional visual information to assist with identification of the SLN as 
demonstrated in Figure 5.
5. Histopathological analysis
The presence of nodal micrometastases (0.2 mm–2 mm) or isolated tumour cells 
(ITC) (<0.2 mm) [9] may be overlooked by standard histopathological analysis, 
with one study that reanalysed 76 neck dissection specimens with serial section-
ing identifying previously undetected micrometastases in 7.9% of specimens 
[25]. These metastases occurred mainly in small (<1 cm) lymph nodes, without 
extranodal extension and therefore would not have been routinely identified on 
preoperative imaging. Figure 6 demonstrates how micrometastases are detected 
more reliably by performing serial sectioning. Another smaller prospective study 
analysed 34 neck dissection specimens with serial sectioning and immunohisto-
chemistry (IHC) in addition to standard haematoxylin–eosin staining (HES) and 
found that 3 patients (8.8%) were upstaged by the additional analysis, with two 
cases of micrometastases and one patient harbouring ITC [26]. Importantly the 
identification of these micrometastases did not warrant further treatment beyond 
the neck dissection which had already been performed [25]. However, the revised 
findings of node positivity has both a staging and prognostic impact on patients.
In another study in the setting of SLNB, serial sectioning and IHC upstaged 5 
of 27 (19%) patients with nodal metastases [8], and a retrospective review of 272 
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patients undergoing SLNB found that 51.7% of their positive sentinel lymph nodes 
were only detected following serial sectioning and IHC [27]. The addition of IHC to 
standard HES increases both the sensitivity and negative predictive value of SLNB 
[16, 28, 29] and has now become part of the standard pathological assessment of 
SLNs in most institutions.
Performing serial sectioning and IHC (cytokeratin – AE1/AE3) is both labour 
and time intensive for the pathologist. By performing a SLNB, the detailed exami-
nation can be focused on the most likely lymph nodes which might harbour micro-
metastatic disease for each individual patient, providing the most precise staging 
and prognostic information.
6. Accuracy in predicting neck status
The Sentinel European Node Trial (SENT) was a large multicentre European 
study investigating SLNB in 415 patients with early OCSCC, of which subclinical 
nodal metastases were identified in 26% of the study population. The findings 
demonstrated the procedure to be safe, reliable and accurate with a SLN identified 
in 99% of cases, with 86% sensitivity, 95% negative predictive value and 14% false 
negative rate [30]. These results have been replicated in other similar studies, albeit 
with lower false negative rates of 2.56% [22] and 9.1% [31], and with higher rates of 
contralateral drainage (23–40%) [31, 32].
SLNB allows for identification of unexpected lymphatic drainage patterns, and 
the SENT trial found that bilateral drainage was identified in 10% of lateralised 
tumours, and 2.4% had exclusive contralateral drainage. The patients with contra-
lateral drainage, 7 of 49 had positive SLNs, with 5 of the patients draining exclu-
sively contralaterally [30]. The rate of contralateral drainage for lateralised tumours 
has been documented in other studies to be as high as 23–40% [31, 32].
The detection of contralateral drainage is a major benefit of performing a SLNB 
as it allows accurate mapping of the lymphatic drainage for each individual patient, 
and for patients with lateralised tumours with contralateral drainage, these nodes 
will not be addressed if they undergo a unilateral END. If there were undetected 
subclinical nodal metastases in these nodes, these patients would then be at risk of a 
contralateral nodal failure.
The accuracy of SLNB has been further investigated by a systematic review/
meta-analysis assessing the performance of SLNB as a staging procedure for OCSCC 
and documented it to be reliable with a sensitivity of 88% and specificity of 99%. 
However, when assessing covariates, performing IHC on the SLN significantly 
improved the sensitivity to 93% [29]. In addition to the differences in process-
ing of specimens, there was a degree of heterogeneity in the articles in relation to 
measurement of failure with a combination of END and clinical follow up to detect 
potential false negatives. Despite this the review demonstrated that SLNB is highly 
accurate across several different institutions, with an improvement in quality of life 
including pain, shoulder mobility and scarring when compared to END [29].
7. Outcomes following sentinel lymph node biopsy
A systematic review assessing outcomes in patients with early OCSCC man-
aged with either a SLNB or END found no significant difference in overall survival 
or disease free survival between the two approaches [33]. This study analysed 5 
separate studies with a total of 560 patients and reported 10 more neck recurrences 
per 1000 patients undergoing the SLNB strategy compared with END, although this 
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was not statistically significant. Conversely SLNB avoided the need for a neck dis-
section in 64% of patients. While this did demonstrate robust outcomes for patients 
treated with SLNB, none of the included studies were randomised and as such the 
overall quality of the evidence was considered low.
Two RCTs have been subsequently published comparing SLNB and END for 
early OCSCC with both demonstrating equivalent oncological outcomes, and their 
findings are summarised in Table 2 and Figure 7. The Senti-MERORL trial was a 
multi-centre RCT with 307 patients that documented a 25% rate of SLN positivity, 
with these patients proceeding to a neck dissection [15]. There was a mean follow 
up of 4.95 years, and rates of nodal recurrence were 10.1% in the neck dissection 
group and 9.3% in the SLNB group, which was not a statistically significant differ-
ence. Equivalent locoregional disease control, disease specific survival and overall 
survival were demonstrated at 2 and 5 years [15]. When looking at the nodal recur-
rences in patients initially classified as pathologically node negative (pN0), there 
were 11 patients (10% of the 109 pN0 patients) in the END group and 8 patients 
(8% of the 99 pN0 patients) in the SLNB group, demonstrating similar rates of 
nodal staging failure between the two strategies.
A Japanese RCT compared 137 patients in the neck dissection arm and 134 
patients in the SLN arm. They found a 34% rate of SLN positivity, and regional 
recurrence rates were 9.5% and 11.2% in the END and SLNB groups respectively. 
Garrel et al. [15] Hasegawa et al. [34]
SLNB (n = 140) END (n = 139) SLNB (n = 134) END (n = 137)













Oral Tongue 124 (89.2%) 119 (85.6%) 109 (81.3%) 114 (83.2%)
Floor of mouth 13 (9.7%) 14 (10.2%)
Lower gingiva 7 (5.2%) 6 (4.4%)
Buccal mucosa 5 (3.7%) 3 (2.2%)
Oropharynx 15 (10.8%) 20 (14.4%)
T1 88 (63%) 91 (66%) 26 (19%) 25 (18%)
T2 52 (37%) 48 (35%) 108 (81%) 112 (82%)
Positive lymph nodes 35 (25%)a 30 (22%) 46 (34%) 34 (25%)
Frozen section/
Imprint cytology
21 (15%) 32 (24%)












Nodal recurrence 13 (9%) 14 (10%) 15 (11%) 13 (10%)
Follow up (months) 56.9 (mean) 59.4 (mean) 37 (median) 37 (median)
Overall Survival 82.2% at 5 y 81.8% at 5 y 87.9% at 3 y 86.6% at 3 ys
aIncludes 2 positive cases out of 8 undergoing END due to localization failure.
Table 2. 
Comparison of two RCTs.
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This study demonstrated equivalent 3 year overall survival and disease free survival 
between the END group (87.9% and 81.3%) and the SLN group (86.6% and 78.7%) 
[34]. Both studies demonstrate high-level evidence to support the use of SLNB as a 
staging procedure for patients with early T1 or T2 OCSCC.
END has an associated morbidity including shoulder dysfunction, pain and 
contour changes [16]. Comparison of morbidity associated with SLNB or a neck 
dissection demonstrates low rates of morbidity overall, however, in one study all the 
morbidity occurred following neck dissection, with no cases of shoulder dysfunc-
tion in the SLNB group [6]. Quality of life assessments demonstrate improved 
tactile sensitivity and reduced pain sensitivity in the SLNB group, with no signifi-
cant difference in the presence of lymphoedema although there was trend towards 
improved symptoms in the sentinel lymph node biopsy group [35]. Functional out-
comes were also assessed in the two RCTs, with the Senti-MERORL study finding an 
initial functional difference between the two groups favouring SLNB at 6 months, 
however this resolved by 12 months [15]. Hasegawa reported that the END group 
had persisting inferior scores at 12 months post operatively, when assessing neck 
stiffness and shoulder dysfunction compared to the SLN group [34].
8. Future directions
It is widely accepted that macrometastases and micrometastases should undergo 
a completion neck dissection, however management of ITC remains uncertain 
without a clear consensus. This is a significant issue as the incidence of ITC ranges 
between 14 and 27% of positive SLNs [27, 30, 36] and the two RCTs managed this 
subgroup with differing strategies. The Senti-MERORL trial treated ITC with obser-
vation, and in those 11 patients there were no nodal recurrences [15]. Conversely 
Figure 7. 
Combined RCT outcomes of nodal recurrence. (Adapted from Garrel et al. [15], Hasegawa et al. [34]).
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the Japanese RCT treated ITC with a completion neck dissection [34], however 
subgroup outcome data was not published. A retrospective Dutch study analysing 
outcomes for patients undergoing SLNB for OCSCC found a SLN positivity rate 
of 22% (107/488 patients) and of these patients, 15 (14%) had ITC, 31 (29%) had 
micrometastases and 61 (57%) had micrometastases. 13 of the patients with ITC 
underwent a neck dissection with 1 patient having additional positive lymph nodes, 
and the other 2 patients had adjuvant radiotherapy, and did not develop regional 
recurrence during follow up [36]. While ITC is considered to represent node nega-
tive disease in the setting of breast cancer [9], management of these patients remain 
uncertain in the setting of OCSCC and further data is required to clarify both the 
natural history and management outcomes for this subset of patients.
Intraoperative lymphoscintigraphy is a developing technique which has par-
ticular utility in the management of oropharyngeal or laryngeal SCC with a SLNB. 
These tumours are unable to be injected with a radiotracer in an awake patient for a 
preoperative assessment [37]. Indocyanine green (ICG) is readily taken up by lym-
phatics and can be identified intraoperatively using a near-infrared fluorescence 
camera to locate the sentinel lymph node [38]. The use of ICG does not cause any 
staining of the primary site as seen with use of patent blue dye, and also provides 
an immediate result, which offers obvious benefits in the setting of intraopera-
tive sentinel lymph node identification. However, it does not provide the detailed 
drainage information with anatomical referencing that is provided by performing 
radiotracer based lymphoscintigraphy with a SPECT/CT. While techniques such 
as skin compression have been described to identify lymphatic drainage and the 
SLN before making a skin incision [37], often the skin flaps need to be raised to 
comprehensively assess the nodal basins [39]. In addition, the ICG signal spreads 
rapidly with time and thus second tier lymph nodes can be hard to distinguish from 
the true sentinel lymph node [40]. The use of hybrid tracers which assemble ICG 
with a radiocolloid to increase the retention time in the sentinel lymph node has 
been described [38], and may have an increasing future role, along with the use of 
intraoperative SPECT scanners, to counteract the disadvantages of using ICG alone. 
However, this is an exciting new tool which can be utilised to expand the utility of 
the SLN technique.
9. Conclusion
Early OCSCCs have a risk of subclinical nodal metastases to the draining 
cervical lymph nodes, which has a negative impact on the patient’s prognosis and 
survival. The subclinical nature limits the ability to identify these with current 
imaging techniques including a PET scan. Despite this, there is recent high quality 
evidence demonstrating that treating this disease surgically has superior survival 
outcomes compared with an observation strategy. However, the patients without 
subclinical nodal metastases (up to 80%) do not gain any benefit by undergoing a 
neck dissection.
SLNB technique represents a minimally invasive technique allowing treat-
ment de-intensification without compromising the oncological efficacy. SLNB 
has been demonstrated to provide an accurate and safe staging procedure to 
assess for subclinical nodal metastases with added benefits over an END includ-
ing identification of out-of-field drainage, as well as a more detailed pathological 
assessment of the SLN However, a high quality multidisciplinary approach is 
required including accurate preoperative lymphoscintigraphy, precise surgical 
technique and detailed pathological assessment to ensure reliable results and 
good patient outcomes.
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